MedTrace Logo

A Study of Antipsychotics in Individuals at Clinical High-risk for Psychosis (the SHARP-2 Study)

NCT04010864 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-10-22

No results posted yet for this study

Summary

The current study will improve knowledge on the effectiveness and safety of the use of antipsychotics at the prodromal phase and on factors influencing the outcome, and will eventually facilitate optimisation of individualised interventions for psychosis prevention and treatment.

Conditions

  • Clinical High-risk

Interventions

OTHER

routine clinical treatment

Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.

Sponsors & Collaborators

  • Ministry of Science and Technology of the People´s Republic of China

    collaborator OTHER_GOV

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Shanghai Municipal Science and Technology Commission

    collaborator OTHER_GOV

  • Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • TianHong Zhang, Doctor · Shanghai Mental Health Center

Eligibility

Min Age
14 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-29
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04010864 on ClinicalTrials.gov